A Phase 1b Trial of Hu5F9-G4 in Combination With Avelumab in Solid Tumor Patients and Checkpoint-Inhibitor-Naive Ovarian Cancer Patients Who Progress Within 6 Months of Prior Platinum Chemotherapy

Trial ID #	NCT03558139
Phase	Ib
Drug Class	Immunotherapy: Checkpoint Inhibitors/PD-L1
Drug Name	Avelumab
Alternate Drug Names	Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio
Drugs in Trial	Avelumab, Magrolimab
Eligible Participant	Platinum resistant or refractory ovarian cancer
Patients Enrolled	18
Therapy Setting	Recurrence
Study Design	Open-Label, Non-randomized
Endpoints	DCR, evaluated per RECIST
Efficacy	DCR: 56% (10SD, n=18)
Clinically Significant Adverse Events	Serious AE: Grade 3-4 AE:
Conclusion	Avelumab+magrolimab is a novel, well-tolerated combination with a 56% stable disease rate in ovarian cancer patients
Reference	Lakhani NJ et al. A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients. J Clin Oncol (2020) 38 (suppl 5; abstr 18) https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.5_suppl.18